Module Specifications.
Current Academic Year 2024 - 2025
All Module information is indicative, and this portal is an interim interface pending the full upgrade of Coursebuilder and subsequent integration to the new DCU Student Information System (DCU Key).
As such, this is a point in time view of data which will be refreshed periodically. Some fields/data may not yet be available pending the completion of the full Coursebuilder upgrade and integration project. We will post status updates as they become available. Thank you for your patience and understanding.
Date posted: September 2024 No Banner module data is available
| |||||||||||||||||||||||||||||||||||||||||||
None |
|||||||||||||||||||||||||||||||||||||||||||
Description Students will be introduced to the concepts of drug design and development including the use of computational modelling. Concepts related to both drug delivery, pro-drugs and hybrid drug molecules are also described. Advanced topics relating to modern drug development will also be covered with emphasis on drug design, solid-form development, clinical trials and final marketing using specific drug examples from the last 15 years. | |||||||||||||||||||||||||||||||||||||||||||
Learning Outcomes 1. Understand the principles of radiopharaceutical design and MRI contrast agents 2. Understand the principles of nucleic acid drugs and antisense therapeutics 3. Prodrug design and applications 4. Introduction to drug delivery 5. Drug design including fragment approaches, QSAR and 3D QSAR with specific examples. | |||||||||||||||||||||||||||||||||||||||||||
All module information is indicative and subject to change. For further information,students are advised to refer to the University's Marks and Standards and Programme Specific Regulations at: http://www.dcu.ie/registry/examinations/index.shtml |
|||||||||||||||||||||||||||||||||||||||||||
Indicative Content and Learning Activities
Pharmaceutical solid form developmentPolymorphism, salts, hydrates, co-crystals; Solid-form risk assessment, solid-form properties regulation of solid forms (ICH 6 & 9); Experimental and computational screening for solid forms, case studies.Computational chemistry in drug developmentKey computational approaches for modelling molecules (ab initio, force fields etc.); conformational analysis of APIs; basic principles of docking.Radiopharmaceuticals and contrast agentsMetal complexes in disease diagnostics, radiopharmaceuticals, magnetic resonance imaging, SPECT, PET, tracer designNucleic acid drugsAntisense therapeutics, gene editing, nucleic acid chemistry, hybrid nucleic acid drugs, nucleic acid chemistry | |||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||
Indicative Reading List
| |||||||||||||||||||||||||||||||||||||||||||
Other Resources None | |||||||||||||||||||||||||||||||||||||||||||